Ozempic, Wegovy get new FDA warning labels

The FDA will now require all GLP-1s, the popular weight loss drug, to adjust their warning labels. This comes after new research shows it can cause people to develop a rare eye condition, which can cause vision loss. Fox News' Natalie Chuck has more. The Food and Drug Administration is placing a new safety warning on popular weight loss drugs like Ozempic and Wegovy, also known as GLP-1s. New research shows they carry a small risk of users developing permanent vision loss. The data is pretty convincing that there is an association. It's pretty consistent over multiple studies. The agency reviewed 126 clinical trials with more than 134,000 patients and discovered some taking the prescription drugs experienced an eye condition called non-arteritic anterior ischemic optic neuropathy. It's when blood flow to the optic nerve is reduced, however the underlying cause is not completely understood. It's like a stroke of the eye. You have less blood flow that is nurturing the optic nerve and the retinal ganglion cells die and cause It causes decreased vision. Research found it's a very rare side effect, impacting about six people out of 100,000 who take a GLP-1. But whatever vision is lost will likely not come back. Over the long term, it's going to stabilize that whatever it's going to, the vision is going to be and you're not going to improve much. There are also other factors which could lead to vision loss, including diabetes, high blood pressure and sleep apnea, common issues among many GLP-1 users. So the FDA noted the GLP might not be solely responsible. If you're suspecting something, then obviously you should get an examination immediately. Moving forward, the FDA said risk of vision loss will be added to all GLP-1 drug labels.